Advice From Investors On Early-Stage Financing

Startup financing may be hard to come by, but now is not the time to ask for less cash. 

Early-Stage Financing Is Available With The Right Approach • Source: Shutterstock

Facing an austere financial climate, some biotech founders are being timid in their financing requests. But asking for less money does not always align with investors’ interests. 

Tari Suprapto, director of search and evaluation at big pharma Novo Nordisk, and an advisor to a biotech founder community...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Growth

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

How To Decarbonize Pharma R&D

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.

IV-Growth (Free-1): Jump-Start Your Exercise With This Mindset Reset

 
• By 

A positive mindset can boost exercise motivation. Learn how mental shifts help you start—and stick with—a healthier fitness routine.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.